Material and Methods
Search Method
Study Selection
Data Extraction
Quality Assessment
Results
Study Characteristics
References | Country | Study design | Study year | FIGO stage | No. of participants |
---|---|---|---|---|---|
Cao et al.11 | China | Prospective, case-control, multicentric study | 2003–2012 | IB1 > 2 cma | 48 |
De Vincenzo et al.12 | Italy | Retrospective, observational, monocentric study | 2014–2018 | IB2 | 13 |
Deng et al.13 | China | Retrospective, observational, monocentric study | – | IB1 > 2 cma | 45 |
Guo et al.14 | China | Retrospective, observational, monocentric study | 2003–2016 | IB1 > 2 cma | 71 |
Kim et al.15 | Korea | Retrospective, observational, monocentric study | 2004–2009 | IB1 > 2 cma | 32 |
Lanowska et al.16 | Germany | Retrospective, observational, monocentric study | 2006–2013 | IB1 > 2 cma IB2 | 18 |
Li et al.17 | China | Retrospective, observational, monocentric study | 2004–2010 | IB1 > 2 cma | 14 |
Li et al.18 | China | Retrospective, observational, monocentric study | 2004–2017 | IB1 > 2 cma | 132 |
Lintner et al.19 | Hungary UK USA | Retrospective, observational, multicentric study | 1999–2006 | IB1 > 2 cma IB2 | 31 |
Lu et al.20 | China | Retrospective, observational, monocentric study | 2005–2012 | IB1 > 2 cma | 6 |
Marchiole et al.21 | France | Retrospective, observational, monocentric study | 2007–2010 | IB–IIA > 2 cma | 7 |
Marchiole et al.22 | France | Retrospective, observational, monocentric study | 2007–2017 | IB1 > 2 cma IB2 IIA1 > 2 cma | 19 |
Okugawa et al.23 | Japan | Retrospective, observational, monocentric study | 2001–2011 | IB1 > 2 cma | 77 |
Pahisa et al.24 | Spain | Retrospective, observational, monocentric study | 1996–2007 | IB1 > 2 cma | 4 |
Park et al.25 | Korea | Retrospective, observational, multicentric study | 2004–2012 | IB1 > 2 cma IB2a | 29 |
Plante et al.26 | Canada | Prospective, observational, monocentric study | 1991–2010 | IB1 > 2 cma IB2a | 14 |
Rendón et al.27 | Colombia | Retrospective, observational, monocentric study | 2009–2019 | IB1 > 2 cma IB2a IIA1 > 2 cma | 25 |
Robova et al.28 | Czech Republic | Retrospective, observational, monocentric study | 2005–2013 | IB1 > 2 cma IB2a | 28 |
Salihi et al.29 | Belgium | Retrospective, observational, monocentric study | 2004–2013 | IB1 > 2 cma IB2a | 5 |
Slama et al.30 | Czech Republic | Retrospective, observational, monocentric study | 2009–2014 | IB1 > 2 cma IBa | 9 |
Tesfai et al.31 | Netherlands | Retrospective, observational, monocentric study | 2006–2018 | IB–IIAa | 19 |
Testa et al.32 | Italy | Retrospective, observational, multicentric study | 2003–2008 | IB1 > 2 cma | 6 |
Ungár et al.33 | USA | Prospective, observational, monocentric study | 1997–2002 | IB1 > 2 cma | 10 |
Vercellino et al.34 | Germany | Retrospective, observational, multicentric study | 2004–2011 | IB1 > 2 cma IB2a | 6 |
Wethington et al.35 | USA | Retrospective, observational, monocentric study | 2001–2011 | IB1 > 2 cma | 29 |
Zusterzeel et al.36 | Netherlands | Retrospective, observational, monocentric study | 2009–2018 | IB2 | 18 |
FIGO International Federation of Gynecology and Obstretics
Outcomes
Surgical Fertility-Sparing Treatment (FST) Outcomes
References | No. of patients | Hystological subtype | Trachelectomy | Lymphadenectomy | Stromal infiltration > 50% (%) | Recurrence | Death | Mean follow-up | Recurrence rate (%) |
---|---|---|---|---|---|---|---|---|---|
Cao et al.11 | 48 | SCC, ADK | 24 ART/24 VRT | NR | 4.17/4.17 | 0/5 | NR | 20 | 0/21.7 |
Deng et al.13 | 45 | SCC, ADK | ART | PLND/PALND | 0 (in recurrences) | 2 | 1 | 61 | 4.4 |
Guo et al.14 | 71 | SCC, ADK, ADS | ART | SLN | 20.3 | 4 | 3 | 75.5 | 5.6 |
Kim et al.15 | 8 | SCC, ADK | LRT | PLND/PALND | 100 | 1 | 1 | 31 | 12.5 |
Li et al.17 | 14 | SCC, ADK, ASK | ART | NR | NR | 0 | 0 | 22.8 | 0 |
Li et al.18 | 132 | SCC, ADK, ASK | ART | NR | 13.8 | 11 | 5 | 56 | 8.3 |
Litner et al.19 | 31 | SCC, ASK, ADK, Anaplastic, glassy cell | ART | PLND | NR | 4 | 2 | 90 | 12.9 |
Okugawa et al.23 | 77 | SCC, ASK, ADK | ART | SLN | NR | 2 | 1 | 72 | 2.6 |
Pahisa et al.24 | 4 | SCC, ADK | VRT | NR | NR | 1 | 0 | NR | 25 |
Park et al.25 | 29 | SCC, ASK, ADK | LRT | PLND | 27.8 | 9 | 1 | 44 | 31 |
Plante et al.26 | 14 | SCC, ADK | VRT | PLND | NR | 6 | 2 | 93 | 42.9 |
Testa et al.32 | 6 | SCC, ADK | ART | PLND | NR | 0 | 0 | 29.6 | 0 |
Ungar et al.33 | 10 | SCC, ADK, glassy cell | ART | PLND | NR | 0 | 0 | 47 | 0 |
Wethington et al.35 | 29 | SCC, ADK, ASK | 22 ART/6 LRT/1 RRT | PLND | NR | 1 (RRT) | 0 | 44 | 3.5 |
Neoadjuvant Chemotherapy FST Outcomes
References | No. of patients | Hystological subtype | Lymph node assesment | Chemotherapy | Surgery | Complete response (%) | Stromal Infiltration > 50% (%) | Recurrence | Death | Mean follow-up | Recurrence rate (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
De Vincenzo et al.12 | 13 | SCC, ADK | PLND/SLN | 3 cisplatin + paclitaxel q21 | Cold-knife conization | 84.5 | NR | 2 | 1 | 37 | 15.4 |
Lanowska et al.16 | 18 | SCC, ADK, ASK | PLND/SLN | 2–3 cisplatin + paclitaxel + ifosfamide | VRT | 50 | NR | 1 | 0 | 23 | 5.5 |
Lu et al.20 | 6 | SCC | SLN | 2 bleomycin + cisplatin + mitomycin q21 | LRT | NR | NR | 0 | 0 | 66 | 0 |
Marchiole et al.21 | 7 | SCC, ADK | PLND | 3–4 cisplatin + paclitaxel + ifosfamide | VRT | 57 | NR | 0 | 0 | 22 | 0 |
Marchiole et al.22 | 19 | SCC, ADK | PLND/SLN | 3–5 TIP (cisplatin + paclitaxel+ ifosfamide) 3–5 TEP (cisplatin + paclitaxel + epirubicin) | LARVT | 63 | NR | 2 | 0 | 79 | 10.5 |
Rendon et al.27 | 25 | SCC, ADK | PLND /SLN | 3–6 range carboplatin/paclitaxel (32%), cisplatin/paclitaxel (28%), paclitaxel/ifosfamide/cisplatin (16%), paclitaxel/cisplatin/5-fluorouracil (12%), 5-fluorouracil/ifosfamide/cisplatin (8%), vincristine/bleomycin/cisplatin in one patient | (5) Cold-knife conization/(11) ART/(9) LRT | 44 | NR | 3 | 0 | 62 | 12 |
Robova et al.28 | 28 | SCC, ADK | PLND/SLN | 3 cisplatin + ifosfamide (SCC); cisplatin + doxorubicin (ADK) | ART/VRT | 21.4 | NR | 4 | 2 | 42 | 14.3 |
Salihi et al.29 | 5 | SCC, ADK | PLND | Cisplatin + paclitaxel + ifosfamide/carboplatin + paclitaxel weekly | Cold-knife conization | 64 | NR | 1 | 0 | 58 | 20 |
Slama et al.30 | 9 | SCC, ADK | SLN | 3 cisplatin+ ifosfamide (SCC); cisplatin + doxorubicin (ADK) | Needle conization/simple vaginal trachelectomy | NR | NR | 2 | 1 | 23 | 22.2 |
Tesfai et al.31 | 19 | SCC, ADK, ADK with clear cell | PLND | 6 cisplatin + paclitaxel | ART | 26.3 | NR | 3 | 1 | 50 | 15.8 |
Varcellino et al.34 | 6 | SCC, ADK, ASK | PLND/PALND | 1 cisplatin + paclitaxel (16.6%) 2–3 cisplatin + paclitaxel + ifosfamide (83.4%) | VRT | 50 | NR | 0 | 0 | 30.6 | 0 |
Zusterzeel et al.36 | 18 | SCC, ADK | PLND | 6 cisplatin + paclitaxel | VRT | 38.8 | NR | 4 | 0 | 49.7 | 22.2 |